On August 10, 2026, Illumina entered into an underwriting agreement to issue and sell $300 million in aggregate principal amount of its 4.950% notes due 2029. The offering is expected to close on August 17, 2026, subject to customary conditions. Illumina intends to use the net proceeds from this transaction, combined with existing cash reserves, to repay its outstanding 4.650% notes maturing on September 9, 2026. This debt refinancing activity is a significant capital structure event that alters the company's near-term liability profile and interest obligations. Illumina operates in the genomics industry, providing DNA sequencing and array-based technologies for life science research and clinical diagnostics.
